Newsletter no 6 2017
Another year is coming to a close, and it has been an intensive one involving several important decisions and events. Construction of our own production facility for stem cells was one key decision that demonstrates that Xintela is advancing strongly in the field of regenerative medicine. The fact that Xintela has now taken this step […]
Newsletter no 5 2017
Xintela has now taken a big step forward in the stem cell project by initiating the construction of its own GMP manufacturing facility for the production of horse as well as human stem cells. This is an important step for Xintela, which shows that our strategy is to become a complete and competitive company in […]
Newsletter no 4 2017
At Xintela, we continue to work intensively to achieve milestones. We now have full focus on the preparation of the GMP (Good Manufacturing Practice) production of our stem cells and preparing for clinical trials in both horses and humans. At the end of May, we announced the signing of a Memorandum of Understanding agreement with […]
Newsletter no 3 2017
Table of contents:Interview with Thomas Areschoug, newly recruited and responsible for Xintela’s Business DevelopmentChanges in Xintela’s R&D TeamMeeting with the European Medical AgencyXintela is participating in the International Cartilage Repair Society Heritage Summit 2017 and start-up event in May/June
Newsletter no 2 2017
A word from the CEO The intense period in Xintela operations has continued and positively so. Previously, we reported on the good progress of both our regenerative medicine and cancer projects, which continue to develop quickly. We are currently focusing on starting stem cell production according to Good Manufacturing Practice (GMP), as well as obtaining […]
Newsletter no 1 2017
Table of contents:The subscription period for shares supported by warrants has startedInterview with Dr. Lisa Fortier regarding the horse studyUpdate on Xintela´s projectsInterview with Greg BatchellerXintela in social media
Newsletter December
The year 2016 has been both intensive and exciting and during which Xintela has experienced strong growth. Together with our current progress in regenerative medicine and cancer, we have also strengthened the company’s structure and resources. We conducted an oversubscribed rights issue and listed the company on Nasdaq First North, in addition to making several […]
Xintela’s Focus in the Cancer Arena
XINMARK is Xintela’s patented integrin technology platform that is being developed with the aim of commercialising innovative and improved treatments in two main areas: regenerative medicine and cancer. Within the cancer arena, Xintela’s research focuses on glioblastoma, an aggressive brain tumour, and this newsletter provides an update on our progress to date.
Focus on commercial development
As our projects progress, it is important to ensure that we have the right competencies to take them towards commercialisation. We are therefore delighted to start the Autumn with two new employees who will strengthen the company’s commercial team. Lina Boreson, with extensive experience from the pharmaceutical industry as, amongst other roles, Head of Marketing, […]
Preparing for an exciting Autumn
Swedish Summer is over and, at Xintela, we are preparing for an exciting Autumn. Since our listing in the Spring, the company has developed in a very positive way and we are on track with the milestones we have set. The purpose of our newsletter is to provide a better understanding of Xintela’s operations, to […]
